John Murphy, CEO The COVID-19 Log haul Foundation<\/p>\n\n\n\n
Importance:<\/strong> Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), is a heterogeneous multisystem disorder that may persist for months or years after acute SARS-CoV-2 infection. Among the mechanisms proposed to explain persistence, reactivation of latent or chronically infecting viruses has emerged as an increasingly plausible contributor. Epstein\u2013Barr virus (EBV), cytomegalovirus (CMV), herpes simplex viruses (HSV), human herpesviruses 6 and 7, and members of the Anelloviridae have all been implicated. The principal unresolved question is whether such viral reactivation is merely a marker of severe systemic immune disturbance or a biological driver of chronic disease.<\/p>\n\n\n\n Observations:<\/strong> SARS-CoV-2 infection produces profound and prolonged perturbations of innate and adaptive immunity, including altered T-cell function, lymphocyte activation, inflammatory signaling, endothelial dysfunction, and metabolic stress. These changes may impair immunologic control of latent viruses. EBV and other herpesviruses can subsequently transition from latency to lytic or abortive replication, generating viral transcripts, proteins, nucleic acids, and additional inflammatory stimuli. A 2026 longitudinal multi-omic study of 1,154 hospitalized patients demonstrated transcriptionally active reactivation of Herpesviridae and Anelloviridae during acute COVID-19, with distinct temporal and anatomical patterns. Importantly, persistent Anelloviridae reactivation during convalescence was associated with PASC symptoms, particularly impaired physical function and fatigue. Viral reactivation was accompanied by alterations in cytokines, activated CD4+ and CD8+ T cells, host transcription, cellular replication pathways, and metabolism.<\/p>\n\n\n\n Conclusions and Relevance:<\/strong> The available evidence supports a model in which SARS-CoV-2 can induce a state of prolonged immune disequilibrium or “dysvirosis,” allowing latent viruses to reactivate and potentially amplify inflammation, endothelial injury, autonomic dysfunction, metabolic impairment, and neuroimmune pathology. The strongest evidence currently establishes association rather than causation. Nevertheless, the convergence of viral transcriptomics, host genomics, immunophenotyping, proteomics, metabolomics, and longitudinal clinical phenotyping provides a biologically coherent framework for understanding a subset of long COVID. Definitive proof will require randomized trials demonstrating that selective suppression of a reactivated virus improves the corresponding long-COVID phenotype.<\/p>\n\n\n\n Long COVID has evolved from a poorly characterized postinfectious syndrome into a recognized chronic disease entity involving the nervous, cardiovascular, pulmonary, gastrointestinal, musculoskeletal, immune, and autonomic systems. Its clinical heterogeneity has resisted reduction to a single mechanism. Current models encompass persistent SARS-CoV-2 antigen, immune dysregulation, autoimmunity, endothelial dysfunction, autonomic disturbance, metabolic impairment, microbiome alteration, and viral persistence or reactivation.\u00b9\u2013\u2074<\/p>\n\n\n\n The hypothesis considered here is narrower but potentially consequential: SARS-CoV-2 may disrupt host antiviral surveillance sufficiently to reactivate viruses that had previously entered a latent or chronic state, and those secondary infections may contribute to the persistence of long-COVID disease.<\/strong><\/p>\n\n\n\n This hypothesis is biologically plausible. More than 90% of adults have been infected with EBV, and many humans harbor multiple persistent viruses simultaneously.\u2075 Herpesviruses have evolved elaborate mechanisms for establishing lifelong latency within B cells, myeloid cells, epithelial tissues, or neurons. Reactivation normally remains constrained by cellular and humoral immune surveillance. Severe physiologic stress, immunosuppression, systemic inflammation, and critical illness can disturb this equilibrium.<\/p>\n\n\n\n SARS-CoV-2 infection represents an unusually powerful perturbation of the immune system.<\/p>\n\n\n\n The question is therefore not whether viral reactivation can occur during COVID-19\u2014it clearly can\u2014but whether reactivation persists sufficiently, occurs in relevant tissues, and produces biological effects capable of contributing to chronic symptoms.<\/p>\n\n\n\n Evidence accumulated through August 2026 increasingly suggests that, at least in a subset of patients, the answer may be yes.<\/p>\n\n\n\n Humans are not biologically virus-free after recovery from an infection.<\/p>\n\n\n\n The human virome contains viruses that persist indefinitely or for prolonged periods, including:<\/p>\n\n\n\n These viruses occupy different anatomical reservoirs.<\/p>\n\n\n\n EBV principally persists in B-cell populations and lymphoid tissues. CMV establishes latency predominantly in cells of the myeloid lineage and can involve endothelial and other tissues. HSV establishes latency in sensory neurons. HHV-6 and HHV-7 possess additional cellular reservoirs. Anelloviruses are ubiquitous, highly persistent DNA viruses whose clinical significance remains incompletely understood.<\/p>\n\n\n\n Consequently, “reactivation” is not a single biological event.<\/p>\n\n\n\n It may mean:<\/p>\n\n\n\n This distinction is essential when interpreting long-COVID studies.<\/p>\n\n\n\n The initiating event is SARS-CoV-2 infection.<\/p>\n\n\n\n During acute infection, viral replication stimulates pattern-recognition receptors and induces interferon, cytokine, chemokine, complement, and adaptive immune responses. Severe disease may produce profound alterations in lymphocyte populations, monocyte activity, endothelial signaling, coagulation, and cellular metabolism.<\/p>\n\n\n\n Longitudinal studies demonstrate that some of these abnormalities can persist well beyond the acute infection.\u00b2,\u2076<\/p>\n\n\n\n The consequences for latent-virus surveillance are potentially profound.<\/p>\n\n\n\n Control of latent herpesviruses depends heavily upon:<\/p>\n\n\n\n SARS-CoV-2 can perturb several of these systems simultaneously.<\/p>\n\n\n\n The resulting state may be conceptualized as immune disequilibrium<\/strong> rather than conventional immunodeficiency.<\/p>\n\n\n\n The patient need not become globally immunosuppressed.<\/p>\n\n\n\n Instead, immune resources may become:<\/p>\n\n\n\n This distinction helps explain why reactivation can occur in otherwise immunocompetent individuals.<\/p>\n\n\n\n EBV has attracted the greatest attention in long-COVID research.<\/p>\n\n\n\n Following primary infection, EBV establishes lifelong latency, principally within B cells. During latency, viral gene expression is tightly restricted. Under appropriate conditions, infected cells can enter the lytic cycle, producing viral proteins and progeny virions.<\/p>\n\n\n\n The transition from latency to lytic replication is controlled by viral immediate-early proteins, including BZLF1 and BRLF1, which initiate a transcriptional cascade leading to viral DNA replication and structural-protein production.\u2077<\/p>\n\n\n\n SARS-CoV-2 infection may facilitate this transition through several mechanisms.<\/p>\n\n\n\n Reduced or dysfunctional antiviral cellular surveillance can allow EBV-infected B cells to escape suppression.<\/p>\n\n\n\n Cytokines and cellular stress may alter B-cell transcriptional programs.<\/p>\n\n\n\n SARS-CoV-2-associated immune activation may create a cellular environment conducive to EBV reactivation.<\/p>\n\n\n\n Viral replication requires substantial metabolic resources and can be favored by changes in cellular metabolism induced by inflammation.<\/p>\n\n\n\n The relationship is therefore potentially bidirectional:<\/p>\n\n\n\n SARS-CoV-2 \u2192 immune disruption \u2192 EBV reactivation \u2192 additional immune stimulation.<\/strong><\/p>\n\n\n\n The evidence is substantial but heterogeneous.<\/p>\n\n\n\n Early studies reported elevated EBV antibody titers among individuals with persistent post-COVID symptoms, particularly fatigue and cognitive impairment.\u2078,\u2079<\/p>\n\n\n\n A particularly influential study found that evidence compatible with recent EBV reactivation was independently associated with fatigue and cognitive dysfunction four months after SARS-CoV-2 infection.\u2079<\/p>\n\n\n\n A 2025 case-control investigation involving 140 patients with persistent fatigue and post-exertional malaise found EBV genetic material in 28.6% compared with 11.3% of recovered controls. The investigators also found differences in EBV-specific antibody responses.\u00b9\u2070<\/p>\n\n\n\n These findings strengthen the association, but several limitations remain:<\/p>\n\n\n\n The critical distinction is therefore between EBV serologic evidence of recent activity<\/strong> and demonstration of transcriptionally active EBV replication in relevant tissues<\/strong>.<\/p>\n\n\n\n The latter provides considerably stronger evidence.<\/p>\n\n\n\n The most important development to date is the 2026 Nature<\/em> study by Maguire and colleagues.<\/p>\n\n\n\n Investigators analyzed longitudinal samples from 1,154 hospitalized patients with COVID-19<\/strong>, using:<\/p>\n\n\n\n The study examined nasal specimens, peripheral-blood mononuclear cells, and endotracheal aspirates over approximately 12 months.<\/p>\n\n\n\n This design is important because it moves beyond indirect serology.<\/p>\n\n\n\n The investigators identified transcriptionally active viruses belonging to:<\/p>\n\n\n\n Among herpesviruses, transcripts from EBV, CMV, HSV-1, and other viruses were detected.<\/p>\n\n\n\n Approximately 47.9% of participants had evidence of reactivation of at least one chronic virus during acute disease<\/strong>, although most had only one virus detected.\u00b9\u00b9<\/p>\n\n\n\n The viruses exhibited strikingly different temporal patterns.<\/p>\n\n\n\n EBV reactivation tended to occur early.<\/p>\n\n\n\n CMV and HSV-1 frequently appeared later.<\/p>\n\n\n\n Anelloviridae displayed yet another kinetic pattern.<\/p>\n\n\n\n This is important because it demonstrates that “viral reactivation” is not one event caused by one mechanism.<\/p>\n\n\n\n It is a dynamic ecological disturbance of the human virome<\/strong>.<\/p>\n\n\n\n The 2026 findings support a broader conceptual framework that may be termed dysvirosis<\/strong>: disruption of the equilibrium among the multiple persistent viruses normally inhabiting the human host.<\/p>\n\n\n\n Under ordinary conditions:<\/p>\n\n\n\n latent virus \u2194 host immune surveillance<\/strong><\/p>\n\n\n\n remains in equilibrium.<\/p>\n\n\n\n SARS-CoV-2 can perturb that equilibrium:<\/p>\n\n\n\n SARS-CoV-2 infection \u2192 immune disruption \u2192 reactivation of latent viruses \u2192 additional antigenic stimulation \u2192 secondary inflammation.<\/strong><\/p>\n\n\n\n The resulting system may contain several simultaneously interacting viral populations.<\/p>\n\n\n\n This model resembles ecological disturbance in other biological systems: perturbation of one component alters the equilibrium of the entire ecosystem.<\/p>\n\n\n\n The concept is particularly attractive because many individuals carry multiple persistent viruses simultaneously.\u00b9\u00b9<\/p>\n\n\n\n CMV differs substantially from EBV.<\/p>\n\n\n\n CMV establishes latency in cells of the myeloid lineage and can reactivate during systemic inflammatory stress.<\/p>\n\n\n\n In the 2026 cohort, CMV transcripts appeared later than EBV and were particularly detectable in respiratory compartments.\u00b9\u00b9<\/p>\n\n\n\n CMV reactivation was associated with:<\/p>\n\n\n\n CMV possesses several properties that make it potentially relevant to long COVID.<\/p>\n\n\n\n It can:<\/p>\n\n\n\n A patient with simultaneous SARS-CoV-2-induced endothelial injury and CMV reactivation could therefore experience a compounded vascular-inflammatory phenotype.<\/p>\n\n\n\n This remains a hypothesis requiring direct clinical testing.<\/p>\n\n\n\n HSV-1 provides another biologically distinct mechanism.<\/p>\n\n\n\n HSV establishes latency primarily in sensory neurons, particularly within trigeminal and dorsal-root ganglia.<\/p>\n\n\n\n Reactivation can result in:<\/p>\n\n\n\n In the 2026 IMPACC study, HSV-1 transcripts were particularly associated with respiratory specimens and appeared later in the acute disease course.\u00b9\u00b9<\/p>\n\n\n\n This raises an intriguing possibility.<\/p>\n\n\n\n If HSV reactivation occurs within neural reservoirs, circulating blood measurements could substantially underestimate the true biological burden.<\/p>\n\n\n\n Thus:<\/p>\n\n\n\n absence of viremia \u2260 absence of tissue reactivation.<\/strong><\/p>\n\n\n\n This principle is likely to become increasingly important in future studies.<\/p>\n\n\n\n One of the most interesting findings of the 2026 work concerns Anelloviridae.<\/p>\n\n\n\n Anelloviruses are small circular single-stranded DNA viruses that are extraordinarily prevalent in humans. Their clinical significance remains incompletely understood.<\/p>\n\n\n\n Unlike EBV or CMV, they are not conventionally considered major human pathogens.<\/p>\n\n\n\n Yet the longitudinal IMPACC analysis found persistent Anelloviridae transcription during convalescence and an association between persistent reactivation and PASC symptoms, particularly:<\/p>\n\n\n\n This finding is important for two reasons.<\/p>\n\n\n\n First, it broadens the concept of viral reactivation beyond herpesviruses.<\/p>\n\n\n\n Second, it raises the possibility that some components of the human virome previously regarded as clinically inert may become biologically relevant when host immune equilibrium is disrupted.<\/p>\n\n\n\n The appropriate conclusion, however, is association, not proof of pathogenicity<\/strong>.<\/p>\n\n\n\n The 2026 study provides particularly compelling evidence that reactivated viruses are associated with measurable changes in host cellular biology.<\/p>\n\n\n\n Viral detection correlated with alterations in host gene expression.<\/p>\n\n\n\n Among reported pathways were changes involving:<\/p>\n\n\n\n These findings matter because they demonstrate that reactivation is not merely a passive laboratory finding.<\/p>\n\n\n\n It occurs within a biologically altered host.<\/p>\n\n\n\n Whether the viral reactivation causes these changes or is caused by them remains unresolved.<\/p>\n\n\n\n But the association is mechanistically coherent.<\/p>\n\n\n\n Viral reactivation was associated with elevations of inflammatory mediators including:<\/p>\n\n\n\n This creates a potential feed-forward loop.<\/p>\n\n\n\n SARS-CoV-2<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n immune activation<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n latent-virus reactivation<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n additional viral antigen<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n cytokine and chemokine production<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n T-cell and monocyte activation<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n endothelial and tissue inflammation<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n additional immune dysregulation<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n greater susceptibility to viral reactivation<\/strong><\/p>\n\n\n\n The system therefore has the potential to become self-amplifying even after the initial SARS-CoV-2 viral burden has declined.<\/p>\n\n\n\n Viral reactivation and autoimmunity should not be regarded as mutually exclusive explanations.<\/p>\n\n\n\n Indeed, they may be mechanistically connected.<\/p>\n\n\n\n EBV is already implicated in the pathogenesis of several autoimmune disorders.\u00b9\u00b2<\/p>\n\n\n\n Several mechanisms could connect viral reactivation to autoimmunity:<\/p>\n\n\n\n Viral antigens may resemble host proteins.<\/p>\n\n\n\n EBV directly affects B-cell biology and can alter the threshold for autoreactive-cell survival.<\/p>\n\n\n\n Tissue injury may expose new self-antigens.<\/p>\n\n\n\n Persistent inflammation may lower the threshold for autoreactive lymphocyte activation.<\/p>\n\n\n\n Inflammation can change which self-peptides are presented to T cells.<\/p>\n\n\n\n Thus:<\/p>\n\n\n\n SARS-CoV-2 \u2192 EBV reactivation \u2192 immune activation \u2192 autoreactive lymphocytes \u2192 chronic inflammation<\/strong><\/p>\n\n\n\n is biologically plausible.<\/p>\n\n\n\n Recent reviews have specifically proposed a connection between COVID-19, EBV reactivation, and autoimmune phenomena.\u00b9\u00b3<\/p>\n\n\n\n The vascular endothelium is a likely convergence point.<\/p>\n\n\n\n Both SARS-CoV-2 and several herpesviruses can influence endothelial biology.<\/p>\n\n\n\n Persistent or recurrent inflammatory signaling can produce:<\/p>\n\n\n\n A 2026 clinical study reported an association among EBV reactivation, circulating blood microaggregates, and long-COVID symptoms.\u00b9\u2074<\/p>\n\n\n\n This is provocative because it connects three previously separated observations:<\/p>\n\n\n\n viral reactivation + abnormal blood rheology + persistent symptoms.<\/strong><\/p>\n\n\n\n However, the causal sequence remains uncertain.<\/p>\n\n\n\n Neurological long COVID may be particularly susceptible to viral reactivation.<\/p>\n\n\n\n Several mechanisms are possible.<\/p>\n\n\n\n HSV can reactivate in sensory ganglia.<\/p>\n\n\n\n Viral antigens can stimulate inflammatory and autoimmune responses.<\/p>\n\n\n\n Long COVID is associated with evidence of altered BBB function.\u00b9\u2075<\/p>\n\n\n\n Inflammation and endothelial dysfunction can impair cerebral perfusion.<\/p>\n\n\n\n Persistent inflammatory signaling can alter neuronal energy metabolism.<\/p>\n\n\n\n Cytokines can alter synaptic function without producing conventional structural neuronal injury.<\/p>\n\n\n\n These mechanisms could collectively produce:<\/p>\n\n\n\n The genetics of viral reactivation is an emerging field.<\/p>\n\n\n\n The probability that a latent virus remains controlled depends partly on host genetic variation affecting:<\/p>\n\n\n\n A major 2025 population-scale study analyzed whole-genome sequencing data from approximately 736,000 individuals<\/strong> in UK Biobank and All of Us. Investigators identified genetic determinants of persistent EBV DNA and found enrichment in immune regulatory regions and genes involved in antigen processing. HLA class II variation appeared particularly important.\u00b9\u2076<\/p>\n\n\n\n This finding has considerable conceptual significance.<\/p>\n\n\n\n It suggests that viral persistence is not simply determined by whether a person has encountered EBV.<\/p>\n\n\n\n Rather:<\/p>\n\n\n\n host genotype \u2192 antigen presentation \u2192 immune surveillance \u2192 probability of persistent viral burden\/reactivation<\/strong><\/p>\n\n\n\n may influence subsequent disease.<\/p>\n\n\n\n This framework could eventually be applied to other persistent viruses.<\/p>\n\n\n\n Persistent SARS-CoV-2 itself introduces another genomic dimension.<\/p>\n\n\n\n A large community surveillance study identified individuals in whom SARS-CoV-2 RNA persisted at high levels for at least 30 days; some remained positive for at least 60 days. Persistent infection was associated with more than 50% higher odds of self-reported long COVID.\u00b9\u2077<\/p>\n\n\n\n Genomic sequencing suggested that some persistent infections underwent substantial within-host evolution.<\/p>\n\n\n\n This creates a critical distinction:<\/p>\n\n\n\n SARS-CoV-2 persistence<\/strong> is not the same phenomenon as reactivation of a latent virus<\/strong>.<\/p>\n\n\n\n Nevertheless, they may interact.<\/p>\n\n\n\n Persistent SARS-CoV-2 antigen could maintain immune stimulation and thereby facilitate reactivation of latent viruses.<\/p>\n\n\n\n Thus some patients may have:<\/p>\n\n\n\n persistent SARS-CoV-2 + reactivated EBV\/CMV\/other viruses<\/strong><\/p>\n\n\n\n rather than one or the other.<\/p>\n\n\n\n Traditional viral diagnostics ask:<\/p>\n\n\n\n Is viral DNA or RNA detectable?<\/p>\n<\/blockquote>\n\n\n\n The newer approach asks:<\/p>\n\n\n\n Is the virus transcriptionally active, in what tissue, at what time, and with what host response?<\/strong><\/p>\n<\/blockquote>\n\n\n\n This is a profound improvement.<\/p>\n\n\n\n RNA-sequencing can detect viral transcripts associated with active gene expression.<\/p>\n\n\n\n Proteomics can identify viral proteins.<\/p>\n\n\n\n Serology can identify immune responses.<\/p>\n\n\n\n Metabolomics can identify physiological consequences.<\/p>\n\n\n\n Host transcriptomics can reveal cellular responses.<\/p>\n\n\n\n Together these measurements can establish a much more persuasive biological chain:<\/p>\n\n\n\n viral transcription \u2192 viral protein \u2192 host response \u2192 physiologic disturbance \u2192 clinical phenotype.<\/strong><\/p>\n\n\n\n The 2026 IMPACC study represents an important realization of this model.\u00b9\u00b9<\/p>\n\n\n\n One of the most important limitations of blood-based research is that viral reactivation may be tissue-specific.<\/p>\n\n\n\n EBV may predominantly reside in:<\/p>\n\n\n\n CMV may involve:<\/p>\n\n\n\n HSV may remain primarily within:<\/p>\n\n\n\n Therefore, a negative blood PCR cannot exclude tissue reactivation.<\/p>\n\n\n\n This is especially important in chronic neurological disease.<\/p>\n\n\n\n A patient could theoretically have:<\/p>\n\n\n\n HSV reactivation in sensory ganglia \u2192 neural inflammation \u2192 neuropathic symptoms<\/strong><\/p>\n\n\n\n while having:<\/p>\n\n\n\n no detectable circulating HSV DNA.<\/strong><\/p>\n\n\n\n The same principle applies to CMV and EBV reservoirs.<\/p>\n\n\n\n Future studies will therefore require tissue-specific approaches, including carefully selected biopsy, imaging, cell-free nucleic-acid measurements, extracellular-vesicle analysis, and perhaps eventually highly sensitive molecular imaging.<\/p>\n\n\n\n Age is another important modifier.<\/p>\n\n\n\n The immune system undergoes progressive changes with aging, including:<\/p>\n\n\n\n These changes may impair control of latent viruses.<\/p>\n\n\n\n The consequence is potentially a synergistic relationship:<\/p>\n\n\n\n aging + SARS-CoV-2-induced immune disruption \u2192 increased probability of viral reactivation.<\/strong><\/p>\n\n\n\n This may partly explain why severe COVID-19 and persistent viral reactivation are disproportionately observed in older or medically vulnerable populations.<\/p>\n\n\n\n It also provides a mechanistic bridge between acute COVID-19 severity and later chronic disease.<\/p>\n\n\n\n Women are disproportionately represented among many long-COVID cohorts.<\/p>\n\n\n\n The mechanisms remain uncertain.<\/p>\n\n\n\n Sex differences in antiviral immunity, B-cell responses, interferon signaling, and autoimmune susceptibility are well established.<\/p>\n\n\n\n Because viral reactivation and autoimmunity are linked, sex-dependent immune regulation could influence whether SARS-CoV-2 produces:<\/p>\n\n\n\n This hypothesis warrants prospective investigation rather than assumption.<\/p>\n\n\n\n The available evidence does not establish a unique “viral-reactivation syndrome.”<\/p>\n\n\n\n Nevertheless, several phenotypes warrant particular investigation.<\/p>\n\n\n\n The association between EBV reactivation and persistent fatigue is among the most reproducible observations.<\/p>\n\n\n\n Persistent Anelloviridae reactivation in the 2026 IMPACC study was associated with physical-function impairment and fatigue.\u00b9\u00b9<\/p>\n\n\n\n Several studies have associated evidence of recent EBV activity with cognitive symptoms.\u2079<\/p>\n\n\n\n HSV and other neurotropic viruses provide a biologically plausible mechanism, although direct causal evidence remains limited.<\/p>\n\n\n\n Immune activation and viral reactivation could alter autonomic function indirectly through endothelial, inflammatory, and neural mechanisms.<\/p>\n\n\n\n CMV and other viruses capable of influencing endothelial biology could theoretically amplify microvascular dysfunction.<\/p>\n\n\n\n These associations require phenotype-specific prospective validation.<\/p>\n\n\n\n Viral reactivation may occur at several stages of long COVID.<\/p>\n\n\n\n During severe acute COVID-19, reactivation may occur because of:<\/p>\n\n\n\n At this stage, reactivation may simply be a marker of severe illness.<\/p>\n\n\n\n Some viruses decline rapidly once the acute inflammatory state resolves.<\/p>\n\n\n\n Others may persist.<\/p>\n\n\n\n This phase may represent the transition from transient reactivation to chronic disease.<\/p>\n\n\n\n Persistent viral transcription or repeated episodes of reactivation could theoretically maintain:<\/p>\n\n\n\n A particularly interesting hypothesis is that intermittent reactivation could contribute to the relapsing-remitting course observed in some patients.<\/p>\n\n\n\n Stress, sleep disruption, additional infections, metabolic disturbances, or immunologic perturbations could theoretically trigger renewed viral activity.<\/p>\n\n\n\n This hypothesis is plausible but not yet proven.<\/p>\n\n\n\n A rigorous JAMA-level assessment must emphasize the limitations.<\/p>\n\n\n\n Severe COVID-19 itself causes viral reactivation.<\/p>\n\n\n\n Therefore:<\/p>\n\n\n\n reactivation \u2192 severe COVID<\/strong><\/p>\n\n\n\n cannot be distinguished automatically from:<\/p>\n\n\n\n severe COVID \u2192 reactivation.<\/strong><\/p>\n\n\n\n Long COVID-associated immune abnormalities could themselves promote viral reactivation.<\/p>\n\n\n\n Elevated EBV antibodies can indicate prior infection or altered immune regulation rather than active replication.<\/p>\n\n\n\n Blood testing may miss localized reactivation.<\/p>\n\n\n\n Different viruses probably produce different biological effects.<\/p>\n\n\n\n To establish causation, reactivation should precede the relevant symptom rather than merely coexist with it.<\/p>\n\n\n\n Perhaps the strongest test is intervention.<\/p>\n\n\n\n If suppressing EBV, CMV, or another virus reliably improves a corresponding phenotype, causality becomes much more persuasive.<\/p>\n\n\n\n The hypothesis of viral reactivation has obvious therapeutic implications.<\/p>\n\n\n\n Potential strategies include:<\/p>\n\n\n\n But treatment must not proceed from association alone.<\/p>\n\n\n\n Valganciclovir, ganciclovir, acyclovir, and related agents have significant toxicities and are not established treatments for long COVID.<\/p>\n\n\n\n There is currently insufficient evidence to recommend routine anti-herpesvirus treatment for PASC.<\/p>\n\n\n\n The appropriate next generation of trials should instead enroll patients according to biological phenotype.<\/p>\n\n\n\n For example:<\/p>\n\n\n\n Trial A:<\/strong> EBV-transcript-positive long-COVID patients with fatigue\/cognitive dysfunction.<\/p>\n\n\n\n Trial B:<\/strong> CMV-transcript-positive patients with vascular or systemic inflammatory phenotypes.<\/p>\n\n\n\n Trial C:<\/strong> HSV-reactivation-positive patients with compatible neurological disease.<\/p>\n\n\n\n Trial D:<\/strong> persistent Anelloviridae-positive patients with severe fatigue and physical-function impairment.<\/p>\n\n\n\n This would test whether viral suppression produces phenotype-specific benefit.<\/p>\n\n\n\n The emerging evidence supports the following conceptual sequence:<\/p>\n\n\n\n SARS-CoV-2 infection<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n acute innate and adaptive immune activation<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n altered T-cell\/NK-cell\/B-cell function<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n impaired surveillance of latent viruses<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n EBV \/ CMV \/ HSV \/ HHV \/ Anelloviridae reactivation<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n viral transcription and protein expression<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n secondary antigenic stimulation<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n cytokine and chemokine production<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n T-cell and monocyte activation<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n endothelial and microvascular dysfunction<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n blood\u2013brain-barrier and tissue-barrier abnormalities<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n metabolic and mitochondrial stress<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n autonomic and neurological dysfunction<\/strong><\/p>\n\n\n\n \u2193<\/p>\n\n\n\n fatigue, post-exertional malaise, cognitive dysfunction, neuropathic symptoms, dysautonomia and multisystem disease<\/strong><\/p>\n\n\n\n with several feedback loops:<\/p>\n\n\n\n viral reactivation \u2194 immune dysregulation<\/strong><\/p>\n\n\n\n viral reactivation \u2194 endothelial dysfunction<\/strong><\/p>\n\n\n\n viral reactivation \u2194 autoimmunity<\/strong><\/p>\n\n\n\n persistent SARS-CoV-2 \u2194 latent-virus reactivation<\/strong><\/p>\n\n\n\n This model accommodates the heterogeneity of long COVID while providing experimentally testable mechanisms.<\/p>\n\n\n\n The greatest practical significance of this research is not the proposition that “EBV causes long COVID.”<\/p>\n\n\n\n That statement is currently too strong.<\/p>\n\n\n\n The more defensible proposition is:<\/p>\n\n\n\n A subset of patients with long COVID may have clinically consequential reactivation of one or more persistent viruses, and those viruses may become therapeutic targets.<\/strong><\/p>\n<\/blockquote>\n\n\n\n The distinction is fundamental.<\/p>\n\n\n\n Future diagnosis may therefore require a matrix of:<\/p>\n\n\n\n Such classification would permit a transition from symptom-based treatment to mechanism-directed therapy.<\/p>\n\n\n\n Seven questions deserve immediate attention.<\/p>\n\n\n\n First<\/strong>, does viral reactivation precede long-COVID symptoms?<\/p>\n\n\n\n Second<\/strong>, does tissue-specific viral activity predict particular phenotypes?<\/p>\n\n\n\n Third<\/strong>, which viral transcripts represent productive replication rather than abortive transcription?<\/p>\n\n\n\n Fourth<\/strong>, which host genetic variants determine susceptibility to reactivation?<\/p>\n\n\n\n Fifth<\/strong>, can viral reactivation induce persistent autoimmunity?<\/p>\n\n\n\n Sixth<\/strong>, does suppressing the reactivated virus improve symptoms?<\/p>\n\n\n\n Seventh<\/strong>, can treatment be targeted before irreversible tissue injury develops?<\/p>\n\n\n\n The sixth question is ultimately decisive.<\/p>\n\n\n\n No amount of association can substitute for therapeutic evidence.<\/p>\n\n\n\n The proposition that SARS-CoV-2 can induce long COVID by reactivating latent viruses has progressed from a speculative hypothesis to a biologically supported and experimentally testable model.<\/p>\n\n\n\n The most compelling new evidence comes from longitudinal multi-omic investigation of more than 1,100 hospitalized patients, demonstrating transcriptionally active reactivation of multiple chronic viruses, including EBV, CMV, HSV, and Anelloviridae, with distinct temporal and anatomical patterns. Viral reactivation was accompanied by characteristic alterations in host transcription, cytokine signaling, immune-cell activation, and metabolism. Most importantly, persistent Anelloviridae reactivation during convalescence was associated with PASC symptoms involving physical function and fatigue.\u00b9\u00b9<\/p>\n\n\n\n The findings fundamentally expand the conceptual model of long COVID.<\/p>\n\n\n\n The relevant question is no longer simply:<\/p>\n\n\n\n “Does SARS-CoV-2 persist?”<\/strong><\/p>\n\n\n\n It is:<\/p>\n\n\n\n “What happens to the entire human virome after SARS-CoV-2 disrupts its host?”<\/strong><\/p>\n\n\n\n The emerging answer is that the virome can become unstable.<\/p>\n\n\n\n EBV may reactivate in B-cell compartments. CMV may emerge in myeloid or endothelial-associated compartments. HSV may reactivate within neural reservoirs. Anelloviridae may remain transcriptionally active during convalescence. Each may produce a distinct immunologic and physiologic consequence.<\/p>\n\n\n\n The resulting state may be understood as post-SARS-CoV-2 virome dysregulation<\/strong>, in which the original infection creates a biological environment permitting secondary viral activity that can perpetuate inflammation after the acute infection has subsided.<\/p>\n\n\n\n This mechanism could also intersect with the other major long-COVID hypotheses. Viral persistence may sustain immune activation; viral reactivation may amplify inflammation; endothelial injury may facilitate tissue damage; BBB dysfunction may permit neuroimmune effects; and chronic antigenic stimulation may promote autoimmunity.<\/p>\n\n\n\n Yet the central scientific caveat remains decisive:<\/p>\n\n\n\n viral reactivation has been demonstrated; its causal contribution to long COVID has not yet been demonstrated at the level required for routine antiviral treatment.<\/strong><\/p>\n\n\n\n The field now possesses the tools to resolve that question. Longitudinal viral transcriptomics, tissue-specific sampling, host genomics, single-cell immune profiling, proteomics, metabolomics, and randomized antiviral trials can establish whether reactivation is merely a biomarker of immune dysfunction or a driver of persistent disease.<\/p>\n\n\n\n If the latter is demonstrated, the therapeutic implications would be substantial.<\/p>\n\n\n\n Long COVID could then be divided into biologically defined subgroups\u2014some dominated by persistent SARS-CoV-2, some by autoimmune disease, some by vascular or metabolic dysfunction, and some by secondary viral reactivation\u2014with treatment selected according to the underlying mechanism.<\/p>\n\n\n\n Such a transition would represent a fundamental change in the management of PASC: from empiric treatment of an enigmatic syndrome to precision treatment of a demonstrable postviral pathophysiology<\/strong>.<\/p>\n\n\n\n John Murphy, CEO The COVID-19 Log haul Foundation Abstract Importance: Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), is a heterogeneous multisystem disorder that may persist for months or […]<\/p>\n","protected":false},"author":2,"featured_media":15960,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1504,1474,152,1325,1535,1541,1533,627,1526,1521],"tags":[],"class_list":["post-15759","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-autonomic-dysfunction","category-endothelial-dysfunction","category-epstein-barr","category-immune-dysregulation","category-metabolic-disturbance","category-microbiome","category-reactivation","category-viral-persistence","category-viral-reactivation-2","category-viral-reactivation"],"_links":{"self":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/15759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15759"}],"version-history":[{"count":3,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/15759\/revisions"}],"predecessor-version":[{"id":15962,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/15759\/revisions\/15962"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/media\/15960"}],"wp:attachment":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15759"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15759"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n\n\n\nIntroduction<\/h5>\n\n\n\n
\n\n\n\nI. The Biological Premise: The Human Virome Is Persistent<\/h5>\n\n\n\n
\n
\n
\n\n\n\nII. SARS-CoV-2 as an Immunologic Perturbation<\/h5>\n\n\n\n
\n
\n
\n\n\n\nIII. EBV Reactivation<\/h5>\n\n\n\n
Immune dysregulation<\/h5>\n\n\n\n
Inflammatory signaling<\/h5>\n\n\n\n
B-cell activation<\/h5>\n\n\n\n
Metabolic stress<\/h5>\n\n\n\n
\n\n\n\nIV. Evidence Linking EBV Reactivation to Long COVID<\/h5>\n\n\n\n
\n
\n\n\n\nV. The 2026 Multi-Omic Evidence<\/h5>\n\n\n\n
\n
\n
\n\n\n\nVI. The Concept of “Dysvirosis”<\/h5>\n\n\n\n
\n\n\n\nVII. CMV Reactivation<\/h5>\n\n\n\n
\n
\n
\n\n\n\nVIII. HSV Reactivation<\/h5>\n\n\n\n
\n
\n\n\n\nIX. Anelloviridae: An Unexpected Development<\/h5>\n\n\n\n
\n
\n\n\n\nX. Viral Reactivation and Host Transcriptomics<\/h5>\n\n\n\n
\n
\n\n\n\nXI. Cytokine Physiology<\/h5>\n\n\n\n
\n
\n\n\n\nXII. The Relationship to Autoimmunity<\/h5>\n\n\n\n
Molecular mimicry<\/h5>\n\n\n\n
B-cell activation<\/h5>\n\n\n\n
Epitope spreading<\/h5>\n\n\n\n
Cytokine amplification<\/h5>\n\n\n\n
Altered antigen presentation<\/h5>\n\n\n\n
\n\n\n\nXIII. Endothelial Physiology<\/h5>\n\n\n\n
\n
\n\n\n\nXIV. Neurological Physiology<\/h5>\n\n\n\n
Direct neural reactivation<\/h5>\n\n\n\n
Immune-mediated injury<\/h5>\n\n\n\n
Blood\u2013brain-barrier dysfunction<\/h5>\n\n\n\n
Microvascular dysfunction<\/h5>\n\n\n\n
Mitochondrial dysfunction<\/h5>\n\n\n\n
Neuroimmune signaling<\/h5>\n\n\n\n
\n
\n\n\n\nXV. Genomics of Viral Reactivation<\/h5>\n\n\n\n
\n
\n\n\n\nXVI. Viral Genomics and Within-Host Evolution<\/h5>\n\n\n\n
\n\n\n\nXVII. Transcriptomics as a New Diagnostic Approach<\/h5>\n\n\n\n
\n
\n
\n\n\n\nXVIII. Tissue Compartmentalization<\/h5>\n\n\n\n
\n
\n
\n
\n\n\n\nXIX. Immunosenescence and Age<\/h5>\n\n\n\n
\n
\n\n\n\nXX. Sex Differences<\/h5>\n\n\n\n
\n
\n\n\n\nXXI. Clinical Phenotypes Potentially Associated With Viral Reactivation<\/h5>\n\n\n\n
Fatigue<\/h5>\n\n\n\n
Post-exertional malaise<\/h5>\n\n\n\n
Cognitive dysfunction<\/h5>\n\n\n\n
Neuropathic symptoms<\/h5>\n\n\n\n
Autonomic dysfunction<\/h5>\n\n\n\n
Vascular symptoms<\/h5>\n\n\n\n
\n\n\n\nXXII. Clinical Course<\/h5>\n\n\n\n
Acute phase<\/h5>\n\n\n\n
\n
Early convalescence<\/h5>\n\n\n\n
Established long COVID<\/h5>\n\n\n\n
\n
Relapsing disease<\/h5>\n\n\n\n
\n\n\n\nXXIII. Why the Evidence Does Not Yet Establish Causation<\/h5>\n\n\n\n
Confounding by disease severity<\/h5>\n\n\n\n
Reverse causality<\/h5>\n\n\n\n
Antibody ambiguity<\/h5>\n\n\n\n
Tissue invisibility<\/h5>\n\n\n\n
Heterogeneity<\/h5>\n\n\n\n
Temporal uncertainty<\/h5>\n\n\n\n
Therapeutic uncertainty<\/h5>\n\n\n\n
\n\n\n\nXXIV. Therapeutic Implications<\/h5>\n\n\n\n
\n
\n\n\n\nXXV. A Mechanistic Model of Viral Reactivation\u2013Associated Long COVID<\/h5>\n\n\n\n
\n\n\n\nXXVI. Implications for Precision Medicine<\/h5>\n\n\n\n
\n
\n
\n\n\n\nXXVII. Future Research Priorities<\/h5>\n\n\n\n
\n\n\n\nConclusion<\/h5>\n\n\n\n
\n\n\n\nNumbered References<\/h5>\n\n\n\n
\n